PLASMA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) IS ASSOCIATED WITH LP(A) IN TYPE 2 DIABETIC PATIENTS

被引：2
|
作者：
Nekaies, Y. [1 ]
Baudin, B. [2 ,3 ]
Sakly, M. [1 ]
Attia, N. [1 ]
机构：
[1] Univ Carthage, Fac Sci Bizerte, Res Unit Integrated Physiol UR11ES33, Bizerte, Tunisia
[2] Biol & Pathol Pole St Antoine Hosp, Dept Biochem, Paris, France
[3] Fac Pharm Chatenay Malabry, Paris, France
来源：
ATHEROSCLEROSIS | 2015年 / 241卷 / 01期
关键词：
D O I：
10.1016/j.atherosclerosis.2015.04.356
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EAS-0862
引用
收藏
页码：E102 / E102
页数：1
相关论文
共 50 条
  • [21] Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside
    Xuhui Bao
    Yongjun Liang
    Hanman Chang
    Tianji Cai
    Baijie Feng
    Konstantin Gordon
    Yuekun Zhu
    Hailian Shi
    Yundong He
    Liyi Xie
    Signal Transduction and Targeted Therapy, 9
  • [22] Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders
    O'Connell, Emma M.
    Lohoff, Falk W.
    FRONTIERS IN NEUROSCIENCE, 2020, 14
  • [23] Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis
    Lu, Xinjie
    CURRENT DRUG TARGETS, 2019, 20 (10) : 1029 - 1040
  • [24] Biological variation of proprotein convertase subtilisin/kexin type 9 (PCSK9) in human serum
    Jabor, Antonin
    Vackova, Tereza
    Kubicek, Zdenek
    Komrskova, Jitka
    Protus, Marek
    Franekova, Janka
    CLINICA CHIMICA ACTA, 2021, 521 : 59 - 63
  • [25] PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future
    Shimada, Yuichi J.
    Cannon, Christopher P.
    EUROPEAN HEART JOURNAL, 2015, 36 (36) : 2415 - U36
  • [26] Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer
    Bhattacharya, Anindita
    Chowdhury, Abhirup
    Chaudhury, Koel
    Shukla, Praphulla Chandra
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1876 (01):
  • [27] Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a novel psoriasis susceptibility locus
    Merleev, A.
    Toussi, A.
    Downing, L.
    Tran, M.
    Nava, J.
    Le, S.
    Marusina, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (05) : S1 - S1
  • [28] Involvement of proprotein convertase subtilisin/kexin type 9 (PCSK9) in aortic valvular calcification
    Poggio, P.
    Songia, P.
    Chiesa, M.
    Barbieri, S.
    Moschetta, D.
    Valerio, V.
    Cavallotti, L.
    Ferri, N.
    Zanotti, I.
    Camera, M.
    EUROPEAN HEART JOURNAL, 2018, 39 : 1057 - 1057
  • [29] Letter to editor regarding effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes
    Seetharaman, Rajmohan
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 191
  • [30] PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Goes "DAMP"
    Silverstein, Roy L.
    CIRCULATION, 2021, 143 (01) : 62 - 64
12345